Nearly a decade of Drugs to Watch

Review the history of drugs identified as potential blockbusters

Download Drugs to Watch 2021

Annually since January 2013, the Clarivate expert team has analyzed and selected the Drugs to Watch. While the underlying process has remained the same, the technologies have evolved, and new tools, such as Drug Timelines & Success Rates, are now available to inform the analysis.

Learn more about our methods

Drug Name Company Therapy Area Year
Tenofovir alafenamide plus emtricitabine plus rilpivirine (Odefsey) Gilead Sciences Inc., Janssen R&D Infectious disease 2016
Trastuzumab deruxtecan (DS-8201a; Enhertu) AstraZeneca plc, Daiichi Sankyo Co. Ltd. Oncology 2020
Trastuzumab emtansine (T-DM1) Roche Oncology 2013
Umeclidinium plus vilanterol (Zephyr) GlaxoSmithKline plc, Theravance Biopharma Inc. Respiratory disease 2013
Upadacitinib (ABT-494; Rinvoq) AbbVie Inc. Excessive immune response/autoimmunity
Vadadustat Akebia Therapeutics Inc., Mitsubishi Tanabe Pharma America Inc., Otsuka Pharmaceutical Chronic disease complication 2020
Valoctocogene roxaparvovec (BMN-270; Valrox) Biomarin Pharmaceutical Inc. Genetic disorder 2020
Venetoclax (Venclexta; Venclyxto) AbbVie Inc. Oncology 2016
Vericiguat  Bayer AG, Merck & Co. Cardiovascular – heart failure 2021
Veruprevir, ritonavir, ombitasvir and dasabuvir (Viekira Pak) AbbVie Inc. Respiratory disease 2015
Vilanterol plus umeclidinium (Anoro Ellipta) GlaxoSmithKline plc, Theravance Biopharma Inc. Respiratory disease 2014

From innovation to bottom line

Access our global intelligence, advanced analytics and global team of experts.

Contact our team